Literature DB >> 8107490

Clonality analysis of childhood ALL in remission: no evidence of clonal hematopoiesis.

L Busque1, R Ilaria, R Tantravahi, H Weinstein, D G Gilliland.   

Abstract

We studied 98 female patients in remission (2-240 months) from childhood ALL to determine the clonality status of their hematopoiesis. Thirty-one (31.6%) were heterozygous at the PGK locus for the BstX1 endonuclease restriction site, permitting X-linked clonality assays to be performed. Two patients were in relapse at the time of study and were excluded. We used the PGK-PCR clonality assay (PPCA) to analyze DNA from PMN and mononuclear cells of the remaining 29 female patients. All (29/29) patients demonstrated polyclonal hematopoiesis. These data show that remission from childhood ALL involves reestablishment of polyclonally derived hematopoiesis in all patients studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107490     DOI: 10.1016/0145-2126(94)90121-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Ling-Wen Ding; Qiao-Yang Sun; Kar-Tong Tan; Wenwen Chien; Anand Mayakonda; Allen Eng Juh Yeoh; Norihiko Kawamata; Yasunobu Nagata; Jin-Fen Xiao; Xin-Yi Loh; De-Chen Lin; Manoj Garg; Yan-Yi Jiang; Liang Xu; Su-Lin Lim; Li-Zhen Liu; Vikas Madan; Masashi Sanada; Lucia Torres Fernández; S S Hema Preethi; Michael Lill; Hagop M Kantarjian; Steven M Kornblau; Satoru Miyano; Der-Cherng Liang; Seishi Ogawa; Lee-Yung Shih; Henry Yang; H Phillip Koeffler
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

2.  Clonality assay of hematopoietic disorders: significance of the buccal epithelium as non-hematopoietic control and of 95% rejection limit as a novel criterion for monoclonality.

Authors:  H Inagaki; A Wakita; H Komatsu; M Kikuchi; A Inagaki; T Eimoto; R Ueda
Journal:  Jpn J Cancer Res       Date:  2001-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.